Coy Heldermon is an Oncology physician affiliated with University of Florida. OpenAlex indexes 130 publications with 1,314 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1600 SW Archer Rd
Gainesville, FL 326103003
Telephone
352-392-3011Registry record last updated 18 Nov 2009.
Clinical trials
- Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Sponsor: University of Florida
- Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients
Sponsor: University of Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Chiesi USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.8%Aromatase Inhibitor65.9%Letrozole89%Anastrozole7%Exemestane4%Part D<11 patientsKinase inhibitor8.1%Ibrance52%Verzenio48%Part D<11 patients+ 1 more class in this area
Nervous system
9.3%Opioid Agonist3.8%Oxycodone Hcl100%Part D≥18 patientsSNRI3.2%Venlafaxine Hcl Er52%Duloxetine Hcl48%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
7.6%Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme3.1%Fabrazyme100%Part D<11 patientsSerotonin-3 Receptor Antagonist2.8%Ondansetron Hcl100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B
University of Florida
FY2026$470,186UH3NS137533 - Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B (Supplement)
University of Florida
FY2025$538,939UG3NS137533 - Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B
University of Florida
FY2025$535,428UG3NS137533
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape
Neural Regeneration Research
2023 - Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
Journal of Managed Care & Specialty Pharmacy
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Dekosky, MD
University of Florida
Brian Hoh, MD
University of Florida
Frederic Kaye, MD
University of Florida
Kelly Foote, MD
University of Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”